Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

Áreas de investigación:

• Sin categoría

Año:

2022

Tipo de publicación:

Artículo

Palabras clave:

Hepatocellular carcinoma, immunosuppression, malignancy, neoplasm, tacrolimus

Autores:

• Rodríguez-Perálvarez, Manuel
• Colmenero, Jordi
• González, Antonio
• Gastaca, Mikel
• Curell, Anna
• Caballero-Marcos, Aránzazu
• Sánchez-Martínez, Ana
• Maira, Tommaso Di
• Herrero, José Ignacio
• Almohalla, Carolina
• Lorente, Sara
• Cuadrado-Lavín, Antonio
• Pascual, Sonia
• López-Garrido, María Ángeles
• González-Grande, Rocio
• Gómez-Orellana, Antonio Manuel
• Alejandre, Rafael
• Zamora-Olaya, Javier
• Bernal-Bellido, Carmen

Journal:

American Journal of Transplantation

Volumen:

22

Número:

6

Páginas:

1671-1682

Mes:

March

ISSN:

1600-6135

BibTex:

@article{TracolimusCancerLiverTransplantation2022, author = "Manuel Rodr{\'i}guez-Per{\'a}lvarez and Jordi Colmenero and Antonio Gonz{\'a}lez and Mikel Gastaca and Anna Curell and Ar{\'a}nzazu Caballero-Marcos and Ana S{\'a}nchez-Mart{\'i}nez and Tommaso Di Maira and Jos{\'e} Ignacio Herrero and Carolina Almohalla and Sara Lorente and Antonio Cuadrado-Lav{\'i}n and Sonia Pascual and Mar{\'i}a {\'A}ngeles L{\'o}pez-Garrido and Rocio Gonz{\'a}lez-Grande and Antonio Manuel G{\'o}mez-Orellana and Rafael Alejandre and Javier Zamora-Olaya and Carmen Bernal-Bellido", abstract = "Cancer is the leading cause of death after liver transplantation (LT). This multicenter case–control nested study aimed to evaluate the effect of maintenance immunosuppression on post-LT malignancy. The eligible cohort included 2495 LT patients who received tacrolimus-based immunosuppression. After 13 922 person/years follow-up, 425 patients (19.7%) developed malignancy (cases) and were matched with 425 controls by propensity score based on age, gender, smoking habit, etiology of liver disease, and hepatocellular carcinoma (HCC) before LT. The independent predictors of post-LT malignancy were older age (HR = 1.06 [95% CI 1.05–1.07]; p r internal neoplasms (after excluding non-melanoma skin cancer). Therefore, tacrolimus minimization, as monitored by CET, is the key to modulate immunosuppression in order to prevent cancer after LT.", awards = "JCR(2022): 9.369 Position: 2/24 (Q1) Category: TRANSPLANTATION.", comments = "JCR(2022): 9.369 Position: 2/24 (Q1) Category: TRANSPLANTATION.", doi = "10.1111/ajt.17021", issn = "1600-6135", journal = "American Journal of Transplantation", keywords = "Hepatocellular carcinoma, immunosuppression, malignancy, neoplasm, tacrolimus", month = "March", note = "JCR(2022): 9.369 Position: 2/24 (Q1) Category: TRANSPLANTATION.", number = "6", pages = "1671--1682", title = "{C}umulative exposure to tacrolimus and incidence of cancer after liver transplantation", url = "doi.org/10.1111/ajt.17021", volume = "22", year = "2022", }

Nota:

JCR(2022): 9.369 Position: 2/24 (Q1) Category: TRANSPLANTATION.

Abstract:

Cancer is the leading cause of death after liver transplantation (LT). This multicenter case–control nested study aimed to evaluate the effect of maintenance immunosuppression on post-LT malignancy. The eligible cohort included 2495 LT patients who received tacrolimus-based immunosuppression. After 13 922 person/years follow-up, 425 patients (19.7%) developed malignancy (cases) and were matched with 425 controls by propensity score based on age, gender, smoking habit, etiology of liver disease, and hepatocellular carcinoma (HCC) before LT. The independent predictors of post-LT malignancy were older age (HR = 1.06 [95% CI 1.05–1.07]; p r internal neoplasms (after excluding non-melanoma skin cancer). Therefore, tacrolimus minimization, as monitored by CET, is the key to modulate immunosuppression in order to prevent cancer after LT.

Comentarios:

JCR(2022): 9.369 Position: 2/24 (Q1) Category: TRANSPLANTATION.